Cannabis use disorder

View All

latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin
Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M

Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement. Aelis, clinical-stage French biotech zeroed in on brain disorders...

Find More

Medical Marijuana Market | Medical Cannabis Market
Medical Marijuana: Is it a blessing in disguise or a curse for humanity?

The influx of companies, the launch of pipeline therapies, and the legalization of marijuana/ cannabis are the major drivers of the medical marijuana market. Cannabis, popularly known as Marijuana, is the most commonly used illicit drug after alcohol. More than 150 Million people regularly smoke marijuana. Appr...

Find More

enzymes FAAH
Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential

Fatty acid amide hydrolase (FAAH) belongs to the serine hydrolase family of enzymes. The identification of this enzyme was led by the discovery and characterization of fatty acid amides, including anandamide and oleamide, as a fundamental class of endogenous signaling molecules. FAAH serves as the major metabolic re...

Find More